BlackRock Fund Advisors recently announced the acquisition of new stake in Lexicon Pharmaceuticals Inc (NASDAQ:LXRX). The institutional investor has increased its shareholding in the Healthcare company by 4.54% to 5.98 million shares with purchase of 0.26 million shares. This fresh investment now brings its stake to 2.44% valued currently at $9.15 million. In addition, Millennium Management LLC raised its holdings by 1.25 million to 3.89 million shares. And Geode Capital Management LLC has lifted its position by 15.52% or 0.29 million shares – to 2.13 million shares.
Currently, there are 244.93M common shares owned by the public and among those 238.79M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 56 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 47 of these insider trades were purchases, accounting for 29,821,074 shares. Insider sales of the common stock occurred on 9 occasions, with total insider shares sold totaling 178,167 shares.
The top 3 mutual fund holders in Lexicon Pharmaceuticals Inc are Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and FCP Medical – BioHealth. Vanguard Total Stock Market ETF owns 3.7 million shares of the company’s stock, all valued at over $5.67 million. iShares Russell 2000 ETF sold 6696.0 shares to see its total holdings shrink to 2.53 million shares valued at over $3.87 million and representing 1.03% of the shares outstanding. FCP Medical – BioHealth now owns shares totaling to 0.70% of the shares outstanding.
However, the script later moved the day high at 1.6000, up 15.94%. The company’s stock has a 5-day price change of 21.21% and 41.59% over the past three months. LXRX shares are trading 4.58% year to date (YTD), with the 12-month market performance down to -31.03% lower. It has a 12-month low price of $0.92 and touched a high of $3.79 over the same period. LXRX has an average intraday trading volume of 2.33 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 11.91%, 26.24%, and -12.40% respectively.
Institutional ownership of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) shares accounts for 77.02% of the company’s 244.93M shares outstanding. Mutual fund holders own 51.43%, while other institutional holders and individual stakeholders account for 66.98% and 10.06% respectively.
It has a market capitalization of $391.89M and a beta (3y monthly) value of 1.22. The earnings-per-share (ttm) stands at -$0.76. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.67% over the week and 8.94% over the month.
Analysts forecast that Lexicon Pharmaceuticals Inc (LXRX) will achieve an EPS of -$0.21 for the current quarter, -$0.22 for the next quarter and -$0.73 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.24 while analysts give the company a high EPS estimate of -$0.18. Comparatively, EPS for the current quarter was -$0.16 a year ago. Earnings per share for the fiscal year are expected to decrease by -26.81%, and 7.73% over the next financial year.
Looking at the support for the LXRX, a number of firms have released research notes about the stock. Jefferies stated their Hold rating for the stock in a research note on March 07, 2023, with the firm’s price target at $3.
